Compare · ALNY vs DRNA
ALNY vs DRNA
Side-by-side comparison of Alnylam Pharmaceuticals Inc. (ALNY) and Dicerna Pharmaceuticals, Inc. (DRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ALNY focuses on Biotechnology: Pharmaceutical Preparations, while DRNA focuses on Major Pharmaceuticals.
- ALNY is the larger of the two at $37.13B, about 12.5x DRNA ($2.96B).
- ALNY has hit the wire 8 times in the past 4 weeks while DRNA has been quiet.
- ALNY has more recent analyst coverage (25 ratings vs 14 for DRNA).
- Company
- Alnylam Pharmaceuticals Inc.
- Dicerna Pharmaceuticals, Inc.
- Price
- $278.14-1.66%
- $38.23+0.61%
- Market cap
- $37.13B
- $2.96B
- 1M return
- -5.57%
- -
- 1Y return
- -10.18%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2004
- 2014
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 14
Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Latest ALNY
- Alnylam to Host Tenth "RNAi Roundtable" Webcast Series
- Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
- Director Pyott David E I sold $1,145,853 worth of shares (3,830 units at $299.18) as part of a pre-agreed trading plan and converted options into 3,830 shares (SEC Form 4)
- SEC Form 4 filed by Director Cravatt Benjamin
- SEC Form 3 filed by new insider Cravatt Benjamin
- SEC Form 144 filed by Alnylam Pharmaceuticals Inc.
- Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
- Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Sigal Charles Elliott was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)
- Director Schulman Amy W was granted 838 shares, increasing direct ownership by 4% to 24,049 units (SEC Form 4)
Latest DRNA
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form 4: Koppel Adam closing all direct ownership in the company
- SEC Form 4: Zeng Ling closing all direct ownership in the company
- SEC Form 4: Weissman James B closing all direct ownership in the company
- SEC Form 4: Smith Cynthia closing all direct ownership in the company